Synthesis and biological evaluation of novel pyranochalcone derivatives as a new class of microtubule stabilizing agents

European Journal of Medicinal Chemistry

Volumn 62, Issue , 2013, Pages 579-589

  Cao, Dong ^a   Han, Xiaolei ^a   Wang, Guangcheng ^a   Yang, Zhuang ^b   Peng, Fei ^a   Ma, Liang ^a   Zhang, Ronghong ^a   Ye, Haoyu ^a   Tang, Minghai ^a   Wu, Wenshuang ^a   Lei, Kai ^a   Wen, Jiaolin ^a   Chen, Jinying ^a   Qiu, Jingxiang ^a   Liang, Xiaolin ^a   Ran, Yan ^a   Sang, Yun ^a   Xiang, Mingli ^a   Peng, Aihua ^a   Chen, Lijuan ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Anticancer activity; Microtubule stabilizing agents; Pyranochalcone; Tubulin

Indexed keywords

1 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 (4 METHOXY 3 ((3 METHYLBUT 2 EN 1 YL)OXY)PHENYL)PROP 2 EN 1 ONE; 1 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 (4 METHOXY 3 (2 (PIPERIDIN 1 YL)ETHOXY)PHENYL)PROP 2 EN 1 ONE; 1 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 (4 METHOXY 3 (2 (PYRROLIDIN 1 YL)ETHOXY)PHENYL)PROP 2 EN 1 ONE; 1 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 (4 METHOXY 3 (2 MORPHOLINOETHOXY)PHENYL)PROP 2 EN 1 ONE; 1 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 (4 METHOXY 3 (PROP 2 YN 1 YLOXY)PHENYL)PROP 2 EN 1 ONE; 2 METHOXY 5 (3 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 OXOPROP 1 EN 1 YL)PHENYL 2 (3 (TRIFLUOROMETHYL)PHENYL)ACETATE; 2 METHOXY 5 (3 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 OXOPROP 1 EN 1 YL)PHENYL 2 (3,4 DICHLOROPHENYL)ACETATE; 2 METHOXY 5 (3 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 OXOPROP 1 EN 1 YL)PHENYL 2 CHLOROACETATE; 2 METHOXY 5 (3 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 OXOPROP 1 EN 1 YL)PHENYL 3 (4 METHOXYLPHENYL)ACRYLATE; 2 METHOXY 5 (3 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 OXOPROP 1 EN 1 YL)PHENYL 3 METHOXYBENZOATE; 2 METHOXY 5 (3 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 OXOPROP 1 EN 1 YL)PHENYL 4 (4 (BIS (2 CHLOROETHYL)AMINO)PHENYL)BUTANOATE; 2 METHOXY 5 (3 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 OXOPROP 1 EN 1 YL)PHENYL 4 BROMOBENZOATE; 2 METHOXY 5 (3 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 OXOPROP 1 EN 1 YL)PHENYL 4 METHYLBENZENESULFONATE; 2 METHOXY 5 (3 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 OXOPROP 1 EN 1 YL)PHENYL ACRYLATE; 2 METHOXY 5 (3 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 OXOPROP 1 EN 1 YL)PHENYL CYCLOPROPANECARBOXYLATE; 2 METHOXY 5 (3 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 OXOPROP 1 EN 1 YL)PHENYL FURAN 2 CARBOXYLATE; 2 METHOXY 5 (3 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 OXOPROP 1 EN 1 YL)PHENYL ISOBUTYRATE; 2 METHOXY 5 (3 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 OXOPROP 1 EN 1 YL)PHENYL METHANESULFONATE; 2 METHOXY 5 (3 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 OXOPROP 1 EN 1 YL)PHENYL PENTANOATE; 2 METHOXY 5 (3 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 OXOPROP 1 EN 1 YL)PHENYL PHENYLMETHANESULFONATE; 2 METHOXY 5 (3 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL) 3 OXOPROP 1 EN 1 YL)PHENYL PROPIONATE; 3 (3 (2 HYDROXYETHOXY) 4 METHOXYPHENYL) 1 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL)PROP 2 EN 1 ONE; 3 (3 (3 DIMETHYLAMINO)PROPOXY) 4 METHOXYPHENYL) 1 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL)PROP 2 EN 1 ONE; 3 (3 (ALLYLOXY) 4 METHOXYPHENYL) 1 (5 METHOXY 2,2 DIMETHYL 2H CHROMEN 8 YL)PROP 2 EN 1 ONE; ANTINEOPLASTIC AGENT; CHALCONE DERIVATIVE; PACLITAXEL; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOTOXICITY; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; G2 PHASE CELL CYCLE CHECKPOINT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; M PHASE CELL CYCLE CHECKPOINT; MICROTUBULE ASSEMBLY; PHENOTYPE; TUMOR CELL LINE; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOPYRANS; CELL LINE; CELL PROLIFERATION; CHALONES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HEP G2 CELLS; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROTUBULES; MOLECULAR STRUCTURE; NEOPLASMS; STRUCTURE-ACTIVITY RELATIONSHIP; TUBULIN MODULATORS;

EID: 84874008047     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.01.007     Document Type: Article

References (30)

1. M.A. Jordan, and L. Wilson Nat. Rev. Cancer 4 2004 253 265
2. R. Heald, and E. Nogales J. Cell. Sci. 115 2002 3 4
3. M. Carr, L.M. Greene, A.J. Knox, D.G. Lloyd, D.M. Zisterer, and M.J. Meegan Eur. J. Med. Chem. 45 2010 5752 5766
4. J.A. Hadfield, S. Ducki, N. Hirst, and A.T. McGown Prog. Cell. Cycle Res. 5 2003 309 325
5. A. Kruczynski, and B.T. Hill Crit. Rev. Oncol. Hematol. 40 2001 159 173
6. M.C. Bibby Drugs Future 27 2002 475 480
7. A.T. McGown, and B.W. Fox Cancer Chemother. Pharmacol. 26 1990 79 81
8. P.B. Schiff, J. Fant, and S.B. Horwitz Nature 277 1979 665 667
9. E.K. Rowinsky, and R.C. Donehower N. Engl. J. Med. 332 1995 1004 1014
10. E.K. Rowinsky Semin. Oncol. 24 1997 1 12
11. G.A. Orr, P. Verdier-Pinard, H. McDaid, and S.B. Horwitz Oncogene 22 2003 7280 7295
12. D.M. Bollag, P.A. McQueney, J. Zhu, O. Hensens, L. Koupal, J. Liesch, M. Goetz, E. Lazarides, and C.M. Woods Cancer Res. 55 1995 2325 2333
13. E. Ter Haar, R.J. Kowalski, E. Hamel, C.M. Lin, R.E. Longely, S.P. Gunasekara, H.S. Rosenkranz, and D.W. Day Biochemistry 35 1996 243 250
14. J.H. Stephen, U.M. Thomas, T.M. David, F. Rejza, W.K. Randall, J.M. Timothy, and L.S. Stuart Chem. Biol. 7 2000 275 286
15. S. Yasushi, T. Toshimasa, and N. Yukimasa Cancer Chemother. Pharmacol. 40 1997 513 520
16. M.V. Reddy, B. Akula, S.C. Cosenza, C.M. Lee, M.R. Mallireddigari, V.R. Pallela, D.R. Subbaiah, A. Udofa, and E.P. Reddy J. Med. Chem. 55 2012 5174 5187
17. H.Y. Ye, A. Fu, W.S. Wu, Y.F. Li, G.C. Wang, M.H. Tang, S.C. Li, S.C. He, S.J. Zhong, H.J. Lai, J.H. Yang, M.L. Xiang, A.H. Peng, and L.J. Chen Fitoterapia 83 8 2012 1402 1408
18. W.S. Wu, H.Y. Ye, G.C. Wang, X.L. Han, J. Hu, M.H. Tang, X.M. Duan, Y. Fan, S.C. He, L. Huang, H.Y. Pei, X.W. Wang, X.X. Li, C.F. Xie, R.H. Zhang, Z. Yuan, Y.Q. Mao, L.J. Chen, Y.Q. Wei, Carcinogenesis, Accepted.
19. D.Y. Kim, K.H. Kim, N.D. Kim, K.Y. Lee, C.K. Han, J.H. Yoon, S.K. Moon, S.S. Lee, and B.L. Seong J. Med. Chem. 49 2006 5664 5670
20. S. Ducki, D. Rennison, M. Woo, A. Kendall, J.F.D. Chabert, A.T. McGown, and N.J. Lawrence Bioorg. Med. Chem. 17 2009 7698 7710
21. K.C. Nicolaou, J.A. Pfefferkorn, and G.Q. Cao Angew. Chem. Int. Ed. 39 2000 734 739
22. K.C. Nicolaou, J.A. Pfefferkorn, A.J. Roecker, G.Q. Cao, S. Barleenga, and H.J. Mitchell J. Am. Chem. Soc. 122 2000 9939 9953
23. T. Narender, and S.A. Gupta Bioorg. Med. Chem. Lett. 14 2004 3913 3916
24. F. Peng, G.C. Wang, X.X. Li, D. Cao, Z. Yang, L. Ma, H.Y. Ye, X.L. Liang, Y. Ran, J.Y. Chen, J.X. Qiu, C.F. Xie, C.Y. Deng, M.L. Xiang, A.H. Peng, Y.Q. Wei, and L.J. Chen Eur. J. Med. Chem. 54 2012 272 280
25. G.C. Wang, W.S. Wu, F. Peng, D. Cao, Z. Yang, L. Ma, N. Qiu, H.Y. Ye, X.L. Han, J.Y. Chen, J.X. Qiu, Y. Sang, X.L. Liang, Y. Ran, A.H. Peng, and Y.Q. Wei Eur. J. Med. Chem. 54 2012 793 803
26. Y.R. Lee, X. Wang, and L.K. Xia Molecules 12 2007 1420 1429
27. S.K. Kumar, E. Hager, C. Pettit, H. Gurulingappa, N.E. Davidson, and S.R. Khan J. Med. Chem. 46 2003 2813 2815
28. B.C. Baguley Mol. Biotechnol. 46 2010 308 316
29. N.J. Lawrence, A.T. McGown, S. Ducki, and J.A. Hadfield Anti-Cancer Drug Des. 15 2000 135 141
30. E. Hamel Cell. Biochem. Biophys. 38 2003 1 21